Methods and compositions for inhibiting integrins using tellurium-containing compounds
AssigneeBioMAS Ltd.
InventorsBenjamin SREDNI, Michael ALBECK
Life of this patent
Estimating the term…
Abstract
Methods and compositions for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are methods and compositions for treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells.
Claims17
A method of treating a condition in which inhibition of an integrin is beneficial, the method comprising administering to a subject in need thereof a therapeutically effective amount of at least one of:
- a compound having general Formula I:
- a compound having general Formula IV:
- wherein:
- each of t, u and v is independently 0 or 1;
- each of m and n is independently 0, 1, 2 or 3;
- Y is selected from the group consisting of ammonium, phsophonium, potassium, sodium and lithium;
- X is a halogen atom;
- and
- each of R1-R22 is independently selected from the group consisting of hydrogen, hydroxyalkyl, hydroxy, thiohydroxy, alkyl, alkenyl, alkenyl, alkoxy, thioalkoxy, halogen, haloalkyl, carboxy, carbonyl, alkylcarbonylalkyl, carboxyalkyl, acyl, amido, cyano, N-monoalkylamidoalkyl, N,N-dialkylamidoalkyl, cyanoalkyl, alkoxyalkyl, carbamyl, cycloalkyl, heteroalicyclic, sulfonyl, sulfinyl, sulfate, amine, aryl, heteroaryl, phosphate, phosphonate and sulfoneamido, and wherein said condition in which inhibition of an integrin is beneficial is associated with angiogenesis.
2-5. (canceled)
(canceled)
A method of treating a subject having a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells, the method comprising administering to the subject a therapeutically effective amount of at least one tellurium-containing compound, said compound having at least one tellurium dioxo moiety, and a therapeutically effective amount of said anti-neoplastic agent.
A method of treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent, said resistance being associated with a high level of expression of an integrin by neoplastic cells, the method comprising:
- a) determining an expression of said integrin by neoplastic cells in a subject with said neoplastic condition;
- and
- b) administering to a subject with a high level of said expression of said integrin a therapeutically effective amount of at least one tellurium-containing compound, said compound having at least one tellurium dioxo moiety, and a therapeutically effective amount of said anti-neoplastic agent.
Dependencies are inferred from the claim text.